🇺🇸 FDA
Pipeline program

KYV-101

KYV101-004

Phase 3 small_molecule active

Quick answer

KYV-101 for Lupus Nephritis, Systemic Sclerosis, Myasthenia Gravis, Rheumatoid Arthritis, Stiff Person Syndrome is a Phase 3 program (small_molecule) at Kyverna Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Kyverna Therapeutics
Indication
Lupus Nephritis, Systemic Sclerosis, Myasthenia Gravis, Rheumatoid Arthritis, Stiff Person Syndrome
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials